Pfizer secures a $10 billion deal to acquire Metsera, outbidding Novo Nordisk. The move boosts Pfizer’s presence in the fast-growing obesity drug market, signaling a major strategic comeback.
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...
Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback